239 related articles for article (PubMed ID: 3012508)
1. [Role of the polyol pathway in the occurrence of degenerative complications of diabetes].
Bosquet F; Grimaldi A
Presse Med; 1986 May; 15(19):879-83. PubMed ID: 3012508
[TBL] [Abstract][Full Text] [Related]
2. Aldose reductase inhibitors.
Kirchain WR; Rendell MS
Pharmacotherapy; 1990; 10(5):326-36. PubMed ID: 2122421
[TBL] [Abstract][Full Text] [Related]
3. [Role of polyols in the development of diabetic complications. Value of aldose-reductase inhibitors].
Brogard JM; Caro-Sampara F; Blicklé JF
Rev Med Interne; 1992; 13(1):69-79. PubMed ID: 1410879
[TBL] [Abstract][Full Text] [Related]
4. Aldose reductase inhibitors and diabetic complications.
Tomlinson DR; Willars GB; Carrington AL
Pharmacol Ther; 1992; 54(2):151-94. PubMed ID: 1438531
[TBL] [Abstract][Full Text] [Related]
5. [The role of polyol pathways in formation of diabetic cataracts].
Sabasiński K; Andrzejewska-Buczko J
Klin Oczna; 1997; 99(6):401-4. PubMed ID: 9685789
[TBL] [Abstract][Full Text] [Related]
6. Metabolic abnormalities contributing to diabetic complications. I. Glucose metabolism in insulin-insensitive pathways.
Anderson JW
Am J Clin Nutr; 1975 Mar; 28(3):273-80. PubMed ID: 123410
[No Abstract] [Full Text] [Related]
7. Recent studies of aldose reductase enzyme inhibition for diabetic complications.
Suzen S; Buyukbingol E
Curr Med Chem; 2003 Aug; 10(15):1329-52. PubMed ID: 12871133
[TBL] [Abstract][Full Text] [Related]
8. Secondary changes in diabetes mellitus with particular reference to retinopathy and neuropathy.
Macfarlane CM
Med Hypotheses; 1985 Aug; 17(4):329-35. PubMed ID: 4046904
[TBL] [Abstract][Full Text] [Related]
9. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Shindo H; Tawata M; Aida K; Onaya T
J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
[TBL] [Abstract][Full Text] [Related]
10. Aldose reductase: a window to the treatment of diabetic complications?
Crabbe MJ; Goode D
Prog Retin Eye Res; 1998 Jul; 17(3):313-83. PubMed ID: 9695797
[TBL] [Abstract][Full Text] [Related]
11. Aldose reductase and its inhibition in the control of diabetic complications.
Narayanan S
Ann Clin Lab Sci; 1993; 23(2):148-58. PubMed ID: 8457142
[TBL] [Abstract][Full Text] [Related]
12. Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhibitor.
Dvornik E; Simard-Duquesne N; Krami M; Sestanj K; Gabbay KH; Kinoshita JH; Varma SD; Merola LO
Science; 1973 Dec; 182(4117):1146-8. PubMed ID: 4270794
[TBL] [Abstract][Full Text] [Related]
13. The polyol pathway. A historical review.
Clements RS
Drugs; 1986; 32 Suppl 2():3-5. PubMed ID: 3792230
[TBL] [Abstract][Full Text] [Related]
14. [Pathogenesis and treatment of diabetic neuropathy].
Grzelec H
Neurol Neurochir Pol; 1991; 25(4):477-84. PubMed ID: 1666426
[TBL] [Abstract][Full Text] [Related]
15. Potential use of aldose reductase inhibitors to prevent diabetic complications.
Zenon GJ; Abobo CV; Carter BL; Ball DW
Clin Pharm; 1990 Jun; 9(6):446-57. PubMed ID: 2114249
[TBL] [Abstract][Full Text] [Related]
16. The pathogenesis and prevention of diabetic neuropathy and nephropathy.
Greene D
Metabolism; 1988 Feb; 37(2 Suppl 1):25-9. PubMed ID: 2828823
[TBL] [Abstract][Full Text] [Related]
17. Discoveries in research on diabetic keratopathy.
Cisarik-Fredenburg P
Optometry; 2001 Nov; 72(11):691-704. PubMed ID: 12363257
[TBL] [Abstract][Full Text] [Related]
18. Role of aldose reductase in the development of diabetes-associated complications.
Kador PF; Kinoshita JH
Am J Med; 1985 Nov; 79(5A):8-12. PubMed ID: 3934965
[TBL] [Abstract][Full Text] [Related]
19. Aldose reductase inhibitors and diabetic complications.
Raskin P; Rosenstock J
Am J Med; 1987 Aug; 83(2):298-306. PubMed ID: 3113248
[No Abstract] [Full Text] [Related]
20. Diabetic and galactosaemic cataracts.
Kador PF; Kinoshita JH
Ciba Found Symp; 1984; 106():110-31. PubMed ID: 6439498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
